Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr235.06M

Enterprise Valuekr39.54M

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding202,640,560

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetExtremely low leverage materially reduces near-term solvency risk and gives the company financing flexibility to support clinical programs. Over 2–6 months this strengthens resilience to credit cost shocks and preserves optionality for partner deals or equity raises without urgent debt pressure.

Focused Alzheimer’s R&D PipelineA concentrated, clearly defined pipeline (ALZ-101 vaccine program) concentrates management and R&D resources on a single high-impact indication. This focus can accelerate milestone delivery, simplify partnership negotiations, and create binary value inflection points attractive to larger pharma.

Clear Commercialization PathwaysThe company’s structural business model—relying on licensing, grants, collaborations and equity—matches typical small biotech economics. This reduces the need to build costly commercial infrastructure and makes value capture via partner deals and non-dilutive grants a durable pathway to funding development.

Bears Say

Near-zero Revenue; Persistent LossesRevenue has effectively collapsed while losses remain large and persistent. Over the medium term this erodes equity, increases dilution pressure on future financings, weakens bargaining power with partners, and makes sustained R&D funding contingent on external capital rather than internal cash generation.

Sustained Negative Cash Flow / High Cash BurnConsistent negative operating and free cash flow creates ongoing dependence on external financing. This raises execution risk for clinical programs, increases probability of dilution or milestone-based partnerships, and could delay trials or development timelines if capital markets tighten.

Very Small Team / Capacity ConstraintsA very small headcount limits internal bandwidth for parallel trials, regulatory work, and commercialization planning. Over months this increases reliance on CROs, consultants, and partners, heightening execution and coordination risk and potentially slowing program delivery or increasing external costs.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr235.06M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on May 13, 2026. The company reported -kr0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.056.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 202,640,560 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.